KR20230027189A - 강박 장애를 치료하기 위한 조성물 및 방법 - Google Patents

강박 장애를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230027189A
KR20230027189A KR1020237001813A KR20237001813A KR20230027189A KR 20230027189 A KR20230027189 A KR 20230027189A KR 1020237001813 A KR1020237001813 A KR 1020237001813A KR 20237001813 A KR20237001813 A KR 20237001813A KR 20230027189 A KR20230027189 A KR 20230027189A
Authority
KR
South Korea
Prior art keywords
dosage form
patient
bocs
weeks
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237001813A
Other languages
English (en)
Korean (ko)
Inventor
블라디미르 코릭
로버트 버만
로렌 아귀아
Original Assignee
바이오하벤 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 테라퓨틱스 리미티드 filed Critical 바이오하벤 테라퓨틱스 리미티드
Publication of KR20230027189A publication Critical patent/KR20230027189A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237001813A 2020-06-24 2021-06-24 강박 장애를 치료하기 위한 조성물 및 방법 Pending KR20230027189A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
US63/043,681 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (1)

Publication Number Publication Date
KR20230027189A true KR20230027189A (ko) 2023-02-27

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001813A Pending KR20230027189A (ko) 2020-06-24 2021-06-24 강박 장애를 치료하기 위한 조성물 및 방법

Country Status (12)

Country Link
US (1) US20230181541A1 (https=)
EP (1) EP4171554A4 (https=)
JP (1) JP7805969B2 (https=)
KR (1) KR20230027189A (https=)
CN (1) CN115968312A (https=)
AU (1) AU2021297249A1 (https=)
BR (1) BR112022025901A2 (https=)
CA (1) CA3187323A1 (https=)
IL (1) IL299301A (https=)
MX (1) MX2022016174A (https=)
PH (1) PH12022553441A1 (https=)
WO (1) WO2021262914A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564187T3 (es) * 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
TW202000205A (zh) * 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
MX2020012377A (es) * 2018-05-27 2021-04-12 Biohaven Therapeutics Ltd Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX2021000515A (es) * 2018-07-22 2021-06-08 Biohaven Therapeutics Ltd Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
US20210315865A1 (en) * 2018-08-16 2021-10-14 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases

Also Published As

Publication number Publication date
AU2021297249A1 (en) 2023-02-23
BR112022025901A2 (pt) 2023-01-10
WO2021262914A1 (en) 2021-12-30
IL299301A (en) 2023-02-01
EP4171554A1 (en) 2023-05-03
US20230181541A1 (en) 2023-06-15
PH12022553441A1 (en) 2024-03-04
MX2022016174A (es) 2023-01-24
CA3187323A1 (en) 2021-12-30
CN115968312A (zh) 2023-04-14
JP2023531919A (ja) 2023-07-26
JP7805969B2 (ja) 2026-01-26
EP4171554A4 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
US20210093629A1 (en) Glutamate agents in the treatment of mental disorders
McElroy et al. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial
US20220152057A1 (en) Methods and compositions for treating various disorders
Weihs et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression
Goldstein et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy
Nitti et al. Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial
Khan et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder
Cohn et al. Double-blind comparison of buspirone and clorazepate in anxious outpatients
TW518218B (en) Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
Sharma et al. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial
KR20240004857A (ko) 우울증 치료를 위한 조성물 및 방법
Lindsay et al. Use of modafinil for the treatment of attention deficit/hyperactivity disorder
JP7805969B2 (ja) 強迫性障害を治療するための組成物及び方法
Enzlin et al. Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings
Dossenbach et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia
JP2013531072A (ja) 統合失調症を処置するための環状アミド誘導体の使用の方法
Pae et al. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial
Ferguson et al. High-dose desvenlafaxine in outpatients with major depressive disorder
Angulo et al. Antidepressant‐induced inhibition of genital vascular responses is reversed by vardenafil in female rabbits
US20240358693A1 (en) Methods of treating pain
Koo et al. Psychopharmacologic approaches to the difficult dermatologic patient.
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
Mak The diagnosis and management of obsessive compulsive disorders in primary care
Del Rosso Cutaneous rosacea: a thorough overview of pathogenesis, clinical presentations, and current recommendations on management
Takekita et al. P. 3. c. 024 Comparison of perospirone and aripiprazole: a 12 weeks, randomised, open-label study in Japanese schizophrenia patients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902